The Cancer Gene Therapy Market is rapidly becoming one of the most revolutionary sectors within the larger oncology sector as a result of innovations in gene engineering, cell therapy, vectors, and precision medicine. Gene therapies have become popular in their use either as substitutes or additions to traditional chemotherapy, radiation therapy, and other modes of treatment, especially for individuals suffering from recurring, resistant, or complex genetic cancers. The successes recorded with CAR-T therapies and advancements in gene editing further reinforce the market’s future prospects.
The Global Cancer Gene Therapy Market was valued at USD 4.07 billion in 2024 and is anticipated to grow to USD 17.35 billion by 2032, with a CAGR of 19.96% over the forecast period of 2025-2032. Growth in the market is being driven by the growing prevalence of cancer globally, investments in biotechnology research, increasing clinical trials, and precision oncology. Advancements in technologies such as CRISPR, CAR-T cell therapy, viral vector technology, and other gene delivery systems have enhanced the capabilities of manufacturers to develop targeted therapies.
To Get More Information on Cancer Gene Therapy Market – Request Free Sample Report
Top 4 Cancer Gene Therapy Companies
1. Merck KGaA
Merck KGaA is a key player in the worldwide oncology and biotechnology market with the company investing to foster the development of innovative treatment strategies. The research and development initiatives of Merck KGaA are consistent with the increasing trend in the pharmaceutical industry to develop precision medicines and drugs targeting complicated and hard to treat cancers. In May 2025, Merck KGaA reported positive clinical results for its USD 85 million investment in a late-stage drug against tenosynovial giant cell tumor. The development highlights the continued commercial interest in innovative oncology treatments and the increasing importance of advanced therapeutic platforms for addressing rare and aggressive tumor types.
2. GSK plc
GSK plc maintains a significant presence in the biotech and pharmaceutical industry sectors, with competencies that allow the company to contribute towards the overall advancement of drugs and specialized oncology treatments. The growing emphasis on precision medicine is opening up new opportunities for pharmaceutical firms to participate in targeted and personalized therapies. As cancer treatments begin to shift towards more specific therapies based on biological and molecular aspects, large pharmaceutical corporations will be expected to play a critical part in enabling clinical and regulatory development of these products. In addition, research collaborations and biotech platforms may continue to be vital in allowing companies to participate in the changing cancer gene therapy environment.
3. Bluebird Bio Inc.
Bluebird Bio has been associated with the development of gene-based therapeutic technologies and has contributed to the broader advancement of the gene therapy industry. The continued maturation of gene engineering platforms is increasing interest in applying similar scientific capabilities to oncology and other complex diseases. The growing number of clinical programs involving genetic modification and cell-based therapies is creating a broader foundation for innovation. Improvements in manufacturing, gene delivery, and long-term therapeutic monitoring are expected to remain important as the industry works to make advanced therapies more scalable and accessible.
4. Genelux Corporation
The Genelux Corporation participates in the development of new approaches in the treatment of cancer, which makes the company a good fit for the rapidly developing field of innovations in the cancer treatment area. The market is slowly shifting towards treatment methods that will allow treating cancer by using certain biological mechanisms while minimizing certain drawbacks of current treatment methods. Clinical studies focused on solid tumors and other difficult cancers create opportunities for those companies that work on developing innovative treatments for cancer
What is Driving the Growth of the Cancer Gene Therapy Market?
One of the key driving forces for the growing market is the increasing prevalence of cancer around the world. Several factors, such as aging population, exposure to the environment, and lifestyle-related risk factors have contributed towards increasing the burden of cancer around the world. The need for conventional treatment remains significant; however, issues related to resistance, recurrence, and side effects have increased the need for targeted therapy.
Gene therapy presents an opportunity for tackling disease mechanisms on the molecular and genetic level. Gene therapy is especially crucial in the field of precision oncology, as the development of treatment strategies is possible based on the biological features of tumors and patients. Based on the data, the number of diagnosed cancers was about 20 million, while the mortality was almost 9.7 million in 2022. Due to the high number of patients, there is a need to invest more into oncology innovations.
The Road Ahead
The future of Cancer Gene Therapy Market will be increasingly shaped by advances made in the areas of precision medicine, CAR-T cell therapy development, gene editing and vector technologies. Though cancerous cells of hematological cancers continue to remain one of the main target markets for commercial activities, the future scope of this market may extend as a result of increased research into solid tumors. Another important development may include the shift of treatments from research institutions to hospitals.
With the market forecast to grow from USD 4.07 billion in 2024 to USD 17.35 billion in 2032, cancer gene therapy is set for strong growth and increasing usage in advanced treatments of cancer. Organizations that have the potential to enhance the accuracy, scale of production, affordability, safety, and accessibility of the therapies are likely to shape the future of cancer treatments.
